Immunotherapy in autoimmune diseases.

Immunotherapy has the potential to modify or re-balance the immune system and hence useful in the management of autoimmune conditions. This article aims to review clinically useful immunotherapies available for treatment of autoimmune conditions, with particular emphasis on Type I diabetes mellitus, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus. A Medline search for the period 1992 to 2002 (10 years) using the unrestricted keywords "immunotherapy AND autoimmune" was done. Full-length articles were selected for reviews based on the contents of their published abstracts. Additional Medline searches were focussed on the keywords "immunotherapy AND diabetes mellitus", "immunotherapy AND multiple sclerosis", "immunotherapy AND rheumatoid arthritis", and "immunotherapy AND systemic lupus erythematosus". Relevant publications referenced in the reviewed literature were further included for review, if not present in the original Medline search. Immunotherapy in Type I diabetes mellitus has focussed on the induction of tolerance to beta cell antigens, and in multiple sclerosis trials of anti-alpha 4 integrins and altered peptide ligand of myelin basic protein (MBP 83-99) showed initial promising results. The use of anti-cytokine therapy (anti-TNF alpha and IL-1Ra) in rheumatoid arthritis has improved the quality of life of patients with refractory disease. The use of anti-CD20 monoclonal antibody for in vivo B cells depletion and early trials of autologous peripheral stem cell transplants represent additional immunomodulatory treatment modalities for systemic lupus erythematosus patients. Better understanding of autoimmune conditions and advances in the production of humanized monoclonal antibodies, promises better immunotherapy in the near future.

• Publication year

  2002

• Venue

  Annals of the Academy of Medicine, Singapore

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.47102/annals-acadmedsg.v31n6p702PMID 12520821
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

  2002cited by this paper
• Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

  2002cited by this paper
• Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

  2002cited by this paper
• Cytokine pathways and joint inflammation in rheumatoid arthritis.

  2001cited by this paper
• Reduced Incidence and Severity of Collagen-Induced Arthritis in Mice Lacking IL-181

  2001cited by this paper
• Cellular and Molecular Pathogenic Mechanisms of Insulin‐Dependent Diabetes Mellitus

  2001cited by this paper
• Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients

  2001cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• Treatment of systemic lupus erythematosus with LJP 394.

  2001cited by this paper
• Autoimmune diseases.

  2001cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Interleukin 18: a pleiotropic participant in chronic inflammation.

  2000cited by this paper
• Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial

  2000cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

  2000cited by this paper
• Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.

  2000cited by this paper
• Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand

  2000cited by this paper
• No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII)

  2000cited by this paper
• Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• A Targeted DNA Vaccine Augments the Natural Immune Response to Self TNF-α and Suppresses Ongoing Adjuvant Arthritis1

  2000cited by this paper
• Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice.

  2000cited by this paper
• Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

  2000cited by this paper
• Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

  2000cited by this paper
• Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells

  2000cited by this paper
• Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Insulin-dependent diabetes mellitus and its animal models.

  1999cited by this paper
• Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library

  1999cited by this paper
• Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.

  1999cited by this paper
• A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response

  1999cited by this paper
• TNF neutralization in MS

  1999cited by this paper
• A proinflammatory role for IL-18 in rheumatoid arthritis.

  1999cited by this paper
• The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

  1999cited by this paper
• Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

  1998cited by this paper
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  1998cited by this paper
• Reduction in circulating dsDNA antibody titer after administration of LJP 394.

  1997cited by this paper
• CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.

  1997cited by this paper
• Deviation of pancreas‐infiltrating cells to Th2 by interleukin‐12 antagonist administration inhibits autoimmune diabetes

  1997cited by this paper
• Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient.

  1996cited by this paper
• Mitoxantrone immunotherapy in multiple sclerosis

  1996cited by this paper
• Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies.

  1995cited by this paper
• Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis.

  1995cited by this paper
• Insulin-dependent diabetes mellitus as an autoimmune disease.

  1994cited by this paper
• Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

  1994cited by this paper
• Human immune response to monoclonal antibodies.

  1994cited by this paper
• Immunization With the Larger Isoform of Mouse Glutamic Acid Decarboxylase (GAD67) Prevents Autoimmune Diabetes in NOD Mice

  1994cited by this paper
• Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes

  1993cited by this paper
• Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

  1993cited by this paper
• Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

  1993cited by this paper
• Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice

  1993cited by this paper
• A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

  1991cited by this paper
• Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

  1991cited by this paper
• Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin.

  1991cited by this paper
• Phage antibodies: filamentous phage displaying antibody variable domains

  1990cited by this paper
• Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase

  1990cited by this paper
• Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda.

  1989cited by this paper
• Insulin dependent diabetes mellitus as an autoimmune disease.

  1988cited by this paper

• TACE reprograms RANKL-mediated differentiation of macrophages by activating the non-canonical pathway of IRF3

  2026cites this paper
• CHIMERIC ANTIGEN RECEPTOR T CELLS: PAST, PRESENT, AND FUTURE

  2024cites this paper
• Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

  2022cites this paper
• Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises

  2020cites this paper
• Immunoactive Photosensitizers Had Photodynamic Immunostimulatory and Immunomodulatory Effects on Mammalian Macrophages.

  2020cites this paper
• The role of lymphocytes in the development and treatment of alopecia areata

  2015cites this paper
• Genes Involved in Systemic and Arterial Bed Dependent Atherosclerosis - Tampere Vascular Study

  2012cites this paper
• Immunological alterations in lupus-prone autoimmune (NZB/NZW) F1 mice by mycelia Chinese medicinal fungus Cordyceps sinensis-induced redistributions of peripheral mononuclear T lymphocytes

  2009cites this paper
• Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.

  2009cites this paper
• BIOENGINEERING MODELS OF CELL SIGNALING

  2007cites this paper
• Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease.

  2005cites this paper
• Mechanism of modulation of T cell responses by N‐palmitoylated peptides

  2004cites this paper
• TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response

  2004cites this paper
• TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response.

  2004cites this paper
• The role of pathogenic B-cell clones in antibody mediated autoimmune disorders.

  2004cites this paper
• Internal Medicine

  2002cites this paper
• Bioengineering models of cell signaling.

  2000cites this paper